Storys aus Lausanne

Debiopharm International SA

DEBIOPHARM AND UBIX THERAPEUTICS LAUNCH RESEARCH TO DEVELOP A NEW ANTI-CANCER MODALITY - ANTIBODY DEGRADUCER® CONJUGATES

Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...

Debiopharm International SA

DEBIOPHARM’S CD37 ANTIBODY DRUG CONJUGATE SHOWS PROMISING PHASE II RESULTS FOR THE TREATMENT OF B-CELL MALIGNANCIES

Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...

nccr - on the move

Foreign Residents in Switzerland Report Satisfaction with the Country of Their Choice

Loterie Romande

224.7 million francs to support social action, sport and culture

Lausanne (ots) - For over a year now, many associations and bodies involved in the areas of social welfare, sport and culture have been battling to deal with repercussions from the public-health crisis. In response to this challenging predicament, Loterie Romande is delighted to announce it will be distributing CHF 224.7 million for public-interest projects, on a par with the figure for the previous year, even though ...

Schweizerischer Nationalfonds / Fonds national suisse

937 million Swiss francs for 3300 new research projects

Bern (ots) - In 2020, researchers submitted 8200 grant applications to the SNSF. 3300 of them were selected for funding in a competitive process. At short notice, the SNSF funded 73 projects on COVID-19. Thousands of SNSF-funded teams explore nature, technology and society. This generates knowledge that is a key driver of progress. In 2020, the SNSF invested 937 million francs in 3300 new projects, selected from 8200 ...

Galderma

Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases

Lausanne, Switzerland (ots/PRNewswire) - - Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists - The program launches the Galderma Excellence in Multichannel Medical Education (GEMME) platform, demonstrating ...

Galderma

#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month

Lausanne, Switzerland (ots/PRNewswire) - - Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition - #RosaceaUnmasked encourages rosacea sufferers to speak with a doctor or dermatologist about the burden of regular ...

Debiopharm International SA

DEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE

Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...

Sommet Education

2021 World University Rankings: Sommet Education Institutions Leading Swiss Hub in Hospitality Management

Lausanne, Switzerland (ots/PRNewswire) - Sommet Educationis the only hospitality education group with two Swiss higher education institutions, Glion and Les Roches, in the top four for Hospitality and Leisure Management education in the QS World University Rankings 2021. According to global higher education analysts ...

Debiopharm International SA

DEBIOPHARM AND GENOME & COMPANY JOIN FORCES TO CREATE NEW HIGHLY SPECIFIC THERAPIES FOR CANCER PATIENTS

Lausanne, Switzerland and Seongnam-si Gyeonggi-do, Republic of Korea (ots) - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading ...

Galderma

Galderma online survey reveals essential COVID-19 mask wearing can be worsening rosacea skin disease

Lausanne, Switzerland (ots/PRNewswire) - - Although essential for public health, new online survey findings show that people with self-reported rosacea* may be experiencing worsening of symptoms due to mask wearing, further increasing the daily burden for people living with this chronic skin disease - Despite ...

Sommet Education

Sommet Education launches its first virtual student Fair

Lausanne, Switzerland (ots/PRNewswire) - Sommet Education, the Leading Education Group in Hospitality with Glion Institute of Higher Education, Les Roches and Ecole Ducasse, has created a one-of-a-kind virtual student Fair around hospitality, culinary and pastry arts, luxury, innovation, digital programs. Glion, Les Roches and École Ducasse offer an exceptional portfolio of graduate and post-graduate programs focusing on ...

Sophia Genetics

SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer

Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy ...

Sophia Genetics

SOPHiA GENETICS Appoints Influential Regulatory Figure Kathy L. Hibbs to Board of Directors

Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Kathy L. Hibbs was nominated to the company's Board of Directors and its Audit Committee. Hibbs is an accomplished healthcare technology executive, currently holding the position of Chief Legal ...

Debiopharm International SA

NUCLEAI AND DEBIOPHARM LAUNCH RESEARCH COLLABORATION UTILIZING NUCLEAI’S AI-POWERED BIOMARKER PLATFORM

Tel Aviv, Israel / Lausanne, Switzerland (ots) - Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to ...

SWISS TXT AG

SWISS TXT subtitling 1000 videos in 4 languages for Play Suisse

Sophia Genetics

Bram Goorden joins SOPHiA GENETICS as Chief Commercial Officer and Head of North America

Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Bram Goorden joined its Executive team, holding the dual role of Chief Commercial Officer and Head of North America. Goorden comes to SOPHiA from Foundation Medicine Inc. (Cambridge, MA) where he held the role of VP of International Business and ...

Firmenich

Firmenich Launches World's First AI-Augmented Laundry Care Fragrances

Geneva (ots/PRNewswire) - Firmenich, the world's largest privately owned fragrance and taste company, has introduced the industry's first laundry care fragrances that fuse Artificial Intelligence (AI) with human creativity. Presented at a customer Sensorium(TM) in Hangzhou, China during the China Cleaning Industry Association (CCIA) conference, the AI-augmented ...

Debiopharm International SA

Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award

Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...

Debiopharm International SA

DEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER

Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...

Sophia Genetics

SOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round

Lausanne, Switzerland and Boston (ots/PRNewswire) - Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company ...

Debiopharm International SA

DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS

Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...

Debiopharm International SA

DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS

Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...

Euro Airport Basel-Mulhouse-Freiburg

3

From 25 nights to just 4 hours: EuroAirport introduces a breakthrough runway survey technology